Acumen Pharmaceuticals(ABOS) - 2022 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company ended 2022 with approximately $193 million in cash and marketable securities, with expectations that this cash runway will last through 2025 [20] - R&D expenses were approximately $32.4 million in 2022, an increase attributed to heightened activity in the ongoing INTERCEPT-AD trial [21] - G&A expenses were $12.9 million in 2022, reflecting an increase due to higher headcount, leading to a loss from operations of $45.2 million [21] Business Line Data and Key Metrics Changes - The company is advancing the development of ACU193, a monoclonal antibody targeting soluble amyloid beta oligomers, with significant progress noted in 2022 [6][10] - Enrollment in the Phase I INTERCEPT-AD trial was completed, with top-line results expected in the third quarter of 2023 [6][14] Market Data and Key Metrics Changes - The treatment landscape for Alzheimer's disease has evolved, with positive results from lecanemab and negative results from gantenerumab and crenezumab influencing the market dynamics [10][11] Company Strategy and Development Direction - The company is preparing for Phase II/III activities based on anticipated successful results from the Phase I study, including a planned end of Phase II meeting with the FDA [9] - The company aims to explore options for a subcutaneous formulation of ACU193 as part of its product development plans [9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the preliminary safety and pharmacokinetic data for ACU193, which supports its differentiated product profile in Alzheimer's treatment [7][15] - The company recognizes the importance of advancements in biomarkers and aims to leverage these insights in developing ACU193 [12] Other Important Information - The company had approximately $1.7 million in cash in its operating accounts at Silicon Valley Bank, which has since been moved to another institution [21] Q&A Session Summary Question: On the interim analysis planned, how does it differ from typical interim analyses? - Management clarified that the interim analysis is more complex and will involve evaluating clinical measures and biomarkers, not just statistical adjustments [23][25] Question: What if there is no clear dose response on the target engagement assay? - Management indicated that the protocol amendment was based on observations from the study, and they remain confident in the modified dose providing valuable information [28][29] Question: How does the FDA view plaque removal in relation to the trial? - Management noted that the FDA considers plaque reduction important for accelerated approval, but the interim analysis is primarily for internal decision-making [31][32] Question: Any updates on MRI scans for patients in Cohort 6? - Management confirmed that Cohort 6 continues as per protocol, with no new information on ARIA-E cases provided [36][37] Question: Is there a correlation between dosing frequency and oligomer-targeted antibodies? - Management explained that oligomer-targeting antibodies require demonstrating antibody excess, which differs from plaque-targeting antibodies [38] Question: How might the protocol amendment impact the commercial profile of ACU193? - Management believes that ACU193 may offer a favorable safety profile compared to plaque-targeting antibodies and is considering the implications for subcutaneous formulation [46][48]